QuantaMatrix

QuantaMatrix P/B

The P/B (Price-to-Book Ratio) of QuantaMatrix (317690.KQ) as of Oct 26, 2026 is 2.04. In the previous year, P/B (Price-to-Book Ratio) was 12.51 — a change of -83.68% (lower).

P/B

2.04

YoY

-83.68%

Last updated:

P/B (Price-to-Book Ratio) of QuantaMatrix is 2025 2.04 . P/B (Price-to-Book Ratio) of QuantaMatrix was 2024 12.51 . It decreases by -83.68% lower compared to the previous year.

The QuantaMatrix P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
-2.03 KRW
Jan 1, 2019
2.79 KRW
Jan 1, 2020
1.42 KRW
Jan 1, 2021
1.40 KRW
Jan 1, 2022
2.05 KRW
Jan 1, 2023
4.51 KRW
Jan 1, 2024
12.51 KRW
Jan 1, 2025
2.04 KRW
The QuantaMatrix P/B history
YEARP/BYoY
2.04-83.68%
12.51+177.46%
4.51+120.09%
2.05+46.42%
1.40-1.70%
1.42-48.99%
2.79-237.39%
-2.03-33.70%
-3.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuantaMatrix Stock analysis

What does QuantaMatrix do? QuantaMatrix Inc. generates revenue through the sale of its multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, and rapid antituberculosis susceptibility testing kits. The company also sells covid kits and conducts research and development for microbial diagnostic products. Its primary customers include healthcare facilities and laboratories requiring advanced diagnostic solutions for microbiological and molecular testing. The firm targets segments focused on infectious disease diagnostics, antimicrobial resistance testing, and rapid tuberculosis detection. The company's product portfolio emphasizes innovative diagnostic tools, with a strong focus on sepsis diagnostics and tuberculosis testing. By offering both equipment and kits, QuantaMatrix addresses diverse needs within the healthcare sector. The firm's research and development activities support continuous product enhancement and expansion into new diagnostic areas. QuantaMatrix Inc. serves the global market for diagnostic equipment, with particular emphasis on regions where infectious disease management is critical. Its products are designed to meet the demands of healthcare providers seeking efficient, accurate, and rapid diagnostic solutions. The company's strategy centers on leveraging its technological expertise to capture market share in specialized diagnostic segments. QuantaMatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about QuantaMatrix stock

P/B (Price-to-Book Ratio) of QuantaMatrix is 2.04 in 2025.

P/B (Price-to-Book Ratio) of QuantaMatrix changed from 12.51 to 2.04, representing a -83.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) QuantaMatrix since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s QuantaMatrix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — QuantaMatrix

All Key Metrics — QuantaMatrix